

Thursday, 16 May, 2019

19:15-	Presidential Reception at Toba Aquarium *The aquarium will be reserved from 18:45 for our reception. *All participants of the symposium will be welcomed regardless whether or not you are a chair or a speaker.
--------	---

Friday, 17 May, 2019

8:30-8:35	Opening Remarks								
8:35-9:05	Special Session 1 <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chair</td> <td>Kinuko Mitani (Dokkyo Medical University School of Medicine)</td> </tr> <tr> <td>Speaker</td> <td> Hiroto Inaba (St. Jude Children's Research Hospital, USA) Precision medicine in pediatric acute lymphoblastic leukemia: a strategy to cure all patients and decrease adverse effects </td> </tr> </table>	Chair	Kinuko Mitani (Dokkyo Medical University School of Medicine)	Speaker	Hiroto Inaba (St. Jude Children's Research Hospital, USA) Precision medicine in pediatric acute lymphoblastic leukemia: a strategy to cure all patients and decrease adverse effects				
Chair	Kinuko Mitani (Dokkyo Medical University School of Medicine)								
Speaker	Hiroto Inaba (St. Jude Children's Research Hospital, USA) Precision medicine in pediatric acute lymphoblastic leukemia: a strategy to cure all patients and decrease adverse effects								
9:15-10:35	Asia-Pacific Session 1 : Bone Marrow Failure <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chairs</td> <td> Shouichi Ohga (Kyushu University Graduate School of Medical Sciences) Yoshiyuki Takahashi (Nagoya University Graduate School of Medicine) </td> </tr> <tr> <td>Speakers</td> <td> Atsushi Narita (Nagoya University Graduate School of Medicine) Randomized trial of two dosages of rabbit antithymocyte globulin in patients with aplastic anemia Jing Chen (Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, China) Upfront alternate donor HSCT for patients with severe aplastic anemia: multi-center prospective clinical trial outcome Ken Ishiyama (Kanazawa University Hospital) Factors affecting response to eltrombopag in patients with refractory aplastic anemia Jong Wook Lee (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea) Safety and efficacy of romiplostim in aplastic anemia refractory to immunosuppressive therapy </td> </tr> </table>	Chairs	Shouichi Ohga (Kyushu University Graduate School of Medical Sciences) Yoshiyuki Takahashi (Nagoya University Graduate School of Medicine)	Speakers	Atsushi Narita (Nagoya University Graduate School of Medicine) Randomized trial of two dosages of rabbit antithymocyte globulin in patients with aplastic anemia Jing Chen (Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, China) Upfront alternate donor HSCT for patients with severe aplastic anemia: multi-center prospective clinical trial outcome Ken Ishiyama (Kanazawa University Hospital) Factors affecting response to eltrombopag in patients with refractory aplastic anemia Jong Wook Lee (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea) Safety and efficacy of romiplostim in aplastic anemia refractory to immunosuppressive therapy				
Chairs	Shouichi Ohga (Kyushu University Graduate School of Medical Sciences) Yoshiyuki Takahashi (Nagoya University Graduate School of Medicine)								
Speakers	Atsushi Narita (Nagoya University Graduate School of Medicine) Randomized trial of two dosages of rabbit antithymocyte globulin in patients with aplastic anemia Jing Chen (Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, China) Upfront alternate donor HSCT for patients with severe aplastic anemia: multi-center prospective clinical trial outcome Ken Ishiyama (Kanazawa University Hospital) Factors affecting response to eltrombopag in patients with refractory aplastic anemia Jong Wook Lee (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea) Safety and efficacy of romiplostim in aplastic anemia refractory to immunosuppressive therapy								
9:15-10:35	Asia-Pacific Session 2 : Neoplastic Lymphoid Cells <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chairs</td> <td> Shigeru Chiba (Faculty of Medicine, University of Tsukuba) Motoko Yamaguchi (Mie University Graduate School of Medicine) </td> </tr> <tr> <td>Speakers</td> <td> Kotaro Arita (Toyama University Graduate School of Medicine and Pharmaceutical Sciences) Establishment of a mouse model of B-cell lymphoma using an in vitro retroviral transduction system Constantine S Tam (St. Vincent Hospital, Peter MacCallum Cancer Center and University of Melbourne, Australia) Exploiting weaknesses in the malignant lymphoid cell for targeted therapy Mamiko Sakata-Yanagimoto (Faculty of Medicine, University of Tsukuba) Genome-based medicine in peripheral T-cell lymphomas Yok-Lam Kwong (Queen Mary Hospital, China) Immune-Checkpoint Inhibition in T-cell and NK-cell Malignancies </td> </tr> </table>	Chairs	Shigeru Chiba (Faculty of Medicine, University of Tsukuba) Motoko Yamaguchi (Mie University Graduate School of Medicine)	Speakers	Kotaro Arita (Toyama University Graduate School of Medicine and Pharmaceutical Sciences) Establishment of a mouse model of B-cell lymphoma using an in vitro retroviral transduction system Constantine S Tam (St. Vincent Hospital, Peter MacCallum Cancer Center and University of Melbourne, Australia) Exploiting weaknesses in the malignant lymphoid cell for targeted therapy Mamiko Sakata-Yanagimoto (Faculty of Medicine, University of Tsukuba) Genome-based medicine in peripheral T-cell lymphomas Yok-Lam Kwong (Queen Mary Hospital, China) Immune-Checkpoint Inhibition in T-cell and NK-cell Malignancies				
Chairs	Shigeru Chiba (Faculty of Medicine, University of Tsukuba) Motoko Yamaguchi (Mie University Graduate School of Medicine)								
Speakers	Kotaro Arita (Toyama University Graduate School of Medicine and Pharmaceutical Sciences) Establishment of a mouse model of B-cell lymphoma using an in vitro retroviral transduction system Constantine S Tam (St. Vincent Hospital, Peter MacCallum Cancer Center and University of Melbourne, Australia) Exploiting weaknesses in the malignant lymphoid cell for targeted therapy Mamiko Sakata-Yanagimoto (Faculty of Medicine, University of Tsukuba) Genome-based medicine in peripheral T-cell lymphomas Yok-Lam Kwong (Queen Mary Hospital, China) Immune-Checkpoint Inhibition in T-cell and NK-cell Malignancies								
10:35-10:45	Break								
10:45-12:25	Plenary Session 1 : T Cells (Normal, Pathologic, and Modified) and Antigen-Presenting Cells <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chairs</td> <td> Norimitsu Kadowaki (Faculty of Medicine, Kagawa University) Itaru Matsumura (Kindai University Faculty of Medicine) </td> </tr> <tr> <td>Speakers</td> <td> Ken-ichi Matsuoka (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences) In vivo modulation of regulatory and effector T cell homeostasis for maximization of GVL effect in allogeneic HSCT Zwi N. Berneman (Antwerp University Hospital and University of Antwerp, Belgium) Dendritic cell vaccination: correlation of clinical effects with T-cell response Naoki Hosen (Osaka University Graduate School of Medicine) The activated conformation of integrin $\beta 7$ is a novel multiple myeloma-specific target for CAR T-cell therapy Madhav Dhodapkar (Emory University, USA) Targeting tissue residence and innate immunity towards protective immunity </td> </tr> </table>	Chairs	Norimitsu Kadowaki (Faculty of Medicine, Kagawa University) Itaru Matsumura (Kindai University Faculty of Medicine)	Speakers	Ken-ichi Matsuoka (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences) In vivo modulation of regulatory and effector T cell homeostasis for maximization of GVL effect in allogeneic HSCT Zwi N. Berneman (Antwerp University Hospital and University of Antwerp, Belgium) Dendritic cell vaccination: correlation of clinical effects with T-cell response Naoki Hosen (Osaka University Graduate School of Medicine) The activated conformation of integrin $\beta 7$ is a novel multiple myeloma-specific target for CAR T-cell therapy Madhav Dhodapkar (Emory University, USA) Targeting tissue residence and innate immunity towards protective immunity				
Chairs	Norimitsu Kadowaki (Faculty of Medicine, Kagawa University) Itaru Matsumura (Kindai University Faculty of Medicine)								
Speakers	Ken-ichi Matsuoka (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences) In vivo modulation of regulatory and effector T cell homeostasis for maximization of GVL effect in allogeneic HSCT Zwi N. Berneman (Antwerp University Hospital and University of Antwerp, Belgium) Dendritic cell vaccination: correlation of clinical effects with T-cell response Naoki Hosen (Osaka University Graduate School of Medicine) The activated conformation of integrin $\beta 7$ is a novel multiple myeloma-specific target for CAR T-cell therapy Madhav Dhodapkar (Emory University, USA) Targeting tissue residence and innate immunity towards protective immunity								
12:25-12:35	Break								
12:35-13:20	Luncheon Seminar 1 (Co-Sponsored by Eisai Co., Ltd.) <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chair</td> <td>Kinuko Mitani (Dokkyo Medical University School of Medicine)</td> </tr> <tr> <td>Speaker</td> <td> Ulrich Jäger (Medical University of Vienna, Austria) Precision medicine of lymphoma based on genetics </td> </tr> </table> Luncheon Seminar 2 (Co-Sponsored by Chugai Pharmaceutical Co., Ltd.) <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chair</td> <td>Norio Komatsu (Juntendo University School of Medicine)</td> </tr> <tr> <td>Speaker</td> <td> Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA) Future prospects for targeting apoptosis in hematopoietic malignancies </td> </tr> </table>	Chair	Kinuko Mitani (Dokkyo Medical University School of Medicine)	Speaker	Ulrich Jäger (Medical University of Vienna, Austria) Precision medicine of lymphoma based on genetics	Chair	Norio Komatsu (Juntendo University School of Medicine)	Speaker	Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA) Future prospects for targeting apoptosis in hematopoietic malignancies
Chair	Kinuko Mitani (Dokkyo Medical University School of Medicine)								
Speaker	Ulrich Jäger (Medical University of Vienna, Austria) Precision medicine of lymphoma based on genetics								
Chair	Norio Komatsu (Juntendo University School of Medicine)								
Speaker	Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA) Future prospects for targeting apoptosis in hematopoietic malignancies								
13:20-14:10	Poster Viewing								
14:10-15:50	JSH/ASH Joint Session : Normal & Pathologic Hematopoietic Stem Cells <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chairs</td> <td> Yasushi Miyazaki (Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences) Kazuya Shimoda (Faculty of Medicine, University of Miyazaki) </td> </tr> <tr> <td>Speakers</td> <td> Fumihiko Ishikawa (RIKEN Center for Integrative Medical Sciences) Developing therapeutic strategies for genetically-complex acute myeloid leukemia Ravi Majeti (Stanford University School of Medicine, USA) Stem cells in human AML Seishi Ogawa (Graduate School of Medicine, Kyoto University / Karolinska Institute, Sweden) Germline DDX41 mutations in the Japanese populations Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA) Guiding blood cancer therapy with mitochondrial BH3 profiling </td> </tr> </table>	Chairs	Yasushi Miyazaki (Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences) Kazuya Shimoda (Faculty of Medicine, University of Miyazaki)	Speakers	Fumihiko Ishikawa (RIKEN Center for Integrative Medical Sciences) Developing therapeutic strategies for genetically-complex acute myeloid leukemia Ravi Majeti (Stanford University School of Medicine, USA) Stem cells in human AML Seishi Ogawa (Graduate School of Medicine, Kyoto University / Karolinska Institute, Sweden) Germline DDX41 mutations in the Japanese populations Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA) Guiding blood cancer therapy with mitochondrial BH3 profiling				
Chairs	Yasushi Miyazaki (Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences) Kazuya Shimoda (Faculty of Medicine, University of Miyazaki)								
Speakers	Fumihiko Ishikawa (RIKEN Center for Integrative Medical Sciences) Developing therapeutic strategies for genetically-complex acute myeloid leukemia Ravi Majeti (Stanford University School of Medicine, USA) Stem cells in human AML Seishi Ogawa (Graduate School of Medicine, Kyoto University / Karolinska Institute, Sweden) Germline DDX41 mutations in the Japanese populations Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA) Guiding blood cancer therapy with mitochondrial BH3 profiling								
15:50-16:05	Break								
16:05-17:45	Plenary Session 2 : Ex Vivo Generation of Blood Cells <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chairs</td> <td> Akifumi Takaori-Kondo (Graduate School of Medicine, Kyoto University) Kohshi Ohishi (Mie University Hospital) </td> </tr> <tr> <td>Speakers</td> <td> Shin-ichiro Fujii (RIKEN Center for Integrative Medical Sciences (IMS) / RIKEN Drug Discovery and Medical Technology Platforms (DMP)) Establishment of a new therapeutic cancer vaccine inducing multifunctional immunity, "artificial adjuvant vector cells (aAVC)" Jeffrey S. Miller (University of Minnesota, Masonic Cancer Center, USA) Novel ways to activate NK cells with specificity to treat cancer Koji Eto (CiRA, Kyoto University / Graduate School of Medicine, Chiba University) Turning stem cells into platelets for next generation transfusion Irwin D. Bernstein (Fred Hutchinson Cancer Research Center, University of Washington, USA) Notch signaling: enhancing the ex vivo generation of cells for therapeutic application </td> </tr> </table>	Chairs	Akifumi Takaori-Kondo (Graduate School of Medicine, Kyoto University) Kohshi Ohishi (Mie University Hospital)	Speakers	Shin-ichiro Fujii (RIKEN Center for Integrative Medical Sciences (IMS) / RIKEN Drug Discovery and Medical Technology Platforms (DMP)) Establishment of a new therapeutic cancer vaccine inducing multifunctional immunity, "artificial adjuvant vector cells (aAVC)" Jeffrey S. Miller (University of Minnesota, Masonic Cancer Center, USA) Novel ways to activate NK cells with specificity to treat cancer Koji Eto (CiRA, Kyoto University / Graduate School of Medicine, Chiba University) Turning stem cells into platelets for next generation transfusion Irwin D. Bernstein (Fred Hutchinson Cancer Research Center, University of Washington, USA) Notch signaling: enhancing the ex vivo generation of cells for therapeutic application				
Chairs	Akifumi Takaori-Kondo (Graduate School of Medicine, Kyoto University) Kohshi Ohishi (Mie University Hospital)								
Speakers	Shin-ichiro Fujii (RIKEN Center for Integrative Medical Sciences (IMS) / RIKEN Drug Discovery and Medical Technology Platforms (DMP)) Establishment of a new therapeutic cancer vaccine inducing multifunctional immunity, "artificial adjuvant vector cells (aAVC)" Jeffrey S. Miller (University of Minnesota, Masonic Cancer Center, USA) Novel ways to activate NK cells with specificity to treat cancer Koji Eto (CiRA, Kyoto University / Graduate School of Medicine, Chiba University) Turning stem cells into platelets for next generation transfusion Irwin D. Bernstein (Fred Hutchinson Cancer Research Center, University of Washington, USA) Notch signaling: enhancing the ex vivo generation of cells for therapeutic application								
17:45-17:55	Break								
17:55-18:25	Oral Session from Poster Presentation : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Chairs</td> <td> Masahiro Hirayama (Mie University Graduate School of Medicine) Tetsuya Nosaka (Mie University Graduate School of Medicine) </td> </tr> </table>	Chairs	Masahiro Hirayama (Mie University Graduate School of Medicine) Tetsuya Nosaka (Mie University Graduate School of Medicine)						
Chairs	Masahiro Hirayama (Mie University Graduate School of Medicine) Tetsuya Nosaka (Mie University Graduate School of Medicine)								
Welcome Reception									

Saturday, 18 May, 2019

8:00-8:45	Morning Seminar 1 (Co-Sponsored by Novartis Pharma K.K.)	
	Chair	Yuzuru Kanakura (Osaka University Graduate School of Medicine)
	Speaker	Itaru Matsumura (Kindai University Faculty of Medicine) Current Status and Future of CML Treatment
	Morning Seminar 2 (Co-Sponsored by Pfizer Japan Inc.)	
	Chair	Hitoshi Kiyoi (Nagoya University Graduate School of Medicine)
	Speaker	Takahiro Yamauchi (Faculty of Medical Sciences, University of Fukui) The Beginning of the New Era of R/R ALL treatment with BESPONSA (Inotuzumab ozogamicin)
8:45-8:55	Break	
8:55-9:25	Special Session 2	
	Chair	Yuzuru Kanakura (Osaka University Graduate School of Medicine)
	Speaker	Makio Ogawa (Medical University of South Carolina, USA) My research career in the US medical system
9:25-9:40	Break	
9:40-11:20	JSH/EHA Joint Session : Normal & Pathologic B Cells	
	Chairs	Ulrich Jäger (Medical University of Vienna, Austria) Junji Suzumiya (Shimane University Hospital)
	Speakers	Tomohiro Kurosaki (WPI Immunology Frontier Research Center, Osaka University / RIKEN Center for Integrative Medical Sciences (IMS)) Function of memory B cells and their generation mechanism
		Hermann Einsele (University Hospital Würzburg, Germany) T cell redirecting strategies in the treatment of B-cell and myeloid malignancies
		Koji Kato (Kyushu University Graduate School of Medical Sciences) A germinal center-associated microenvironmental signature predicts clinical outcome of diffuse large B-cell lymphoma
		Ulrich Jäger (Medical University of Vienna, Austria) Drug sensitivity testing for treatment-decisions in B-cell-lymphomas
11:20-11:30	Break	
11:30-12:15	Luncheon Seminar 3 (Co-Sponsored by Bristol-Myers Squibb K.K.)	
	Chair	Koichi Akashi (Kyushu University Graduate School of Medical Sciences)
	Speaker	Hermann Einsele (University of Würzburg, Germany) Immunotherapy for multiple myeloma targeting CD38, SLAMF7 and the future
	Luncheon Seminar 4 (Co-Sponsored by NIPPON SHINYAKU CO., LTD.)	
	Chair	Masahiro Kizaki (Saitama Medical Center, Saitama Medical University)
	Speaker	Ravi Majeti (Stanford University School of Medicine, USA) Clonal Evolution in Human AML
12:15-12:25	Break	
12:25-12:55	Special Session 3	
	Chair	Koichi Akashi (Kyushu University Graduate School of Medical Sciences)
	Speaker	Hiroshi Shiku (Mie University Graduate School of Medicine) Adoptive cell therapy with TCR-Gene engineered T cells and beyond
12:55-13:00	Closing Remarks	